- Home
- FGI vs BCAB Comparison
FGI vs BCAB Comparison
Compare FGI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FGI | BCAB |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | 420 | 41 |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FGI | BCAB |
|---|---|---|
| Price | $3.67 | $4.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.2K | ★ 868.2K |
| Earning Date | 04-09-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.12 |
| 52 Week High | $12.62 | $6.52 |
Technical Indicators
Market Signals| Indicator | FGI | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 79.81 |
| Support Level | $3.37 | $0.36 |
| Resistance Level | $5.05 | N/A |
| Average True Range (ATR) | 0.72 | 0.28 |
| MACD | 0.09 | 0.51 |
| Stochastic Oscillator | 24.07 | 68.60 |
Price Performance
Historical ComparisonAbout FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.